Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Immucell (ICCC) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Immucell (ICCC) over the last 16 years, with Q3 2025 value amounting to $3.1 million.

  • Immucell's Cost of Revenue fell 2901.96% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.4 million, marking a year-over-year increase of 2031.91%. This contributed to the annual value of $18.6 million for FY2024, which is 3638.88% up from last year.
  • Immucell's Cost of Revenue amounted to $3.1 million in Q3 2025, which was down 2901.96% from $3.6 million recorded in Q2 2025.
  • In the past 5 years, Immucell's Cost of Revenue ranged from a high of $5.0 million in Q1 2024 and a low of $2.2 million during Q2 2022
  • Its 5-year average for Cost of Revenue is $3.4 million, with a median of $3.0 million in 2022.
  • Per our database at Business Quant, Immucell's Cost of Revenue surged by 7046.03% in 2024 and then plummeted by 2901.96% in 2025.
  • Over the past 5 years, Immucell's Cost of Revenue (Quarter) stood at $2.9 million in 2021, then increased by 1.23% to $2.9 million in 2022, then skyrocketed by 41.49% to $4.1 million in 2023, then increased by 19.13% to $4.9 million in 2024, then plummeted by 36.11% to $3.1 million in 2025.
  • Its last three reported values are $3.1 million in Q3 2025, $3.6 million for Q2 2025, and $4.7 million during Q1 2025.